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Summary 
Background Spinal muscular atrophy (SMA) is a progressive motor neuron disease causing loss of motor function 
and reduced life expectancy, for which limited treatment is available. We investigated the safety and efficacy of 
olesoxime in patients with type 2 or non-ambulatory type 3 SMA. 
 
Methods This randomised, double-blind, placebo-controlled, phase 2 study was done in 22 neuromuscular care 
centres in Belgium, France, Germany, Italy, Netherlands, Poland, and the UK. Safety and efficacy of olesoxime were 
assessed in patients aged 3–25 years with genetically confirmed type 2 or non-ambulatory type 3 SMA. A centralised, 
computerised randomisation process allocated patients (2:1 with stratification by SMA type and centre) to receive 
olesoxime (10 mg/kg per day) in an oral liquid suspension or placebo for 24 months. Patients, investigators assessing 
outcomes, and sponsor study personnel were masked to treatment assignment. The primary outcome measure was 
change from baseline compared with 24 months between the two treatment groups in functional domains 1 and 2 of 
the Motor Function Measure (MFM D1 + D2) assessed in the full analysis population. A shorter, 20-item version of the 
MFM, which was specifically adapted for young children, was used to assess patients younger than 6 years. Safety was 
assessed in the intention-to-treat population. The trial is registered with ClinicalTrials.gov, number NCT01302600. 
 
Findings The trial was done between Nov 18, 2010, and Oct 9, 2013. Of 198 patients screened, 165 were randomly 
assigned to olesoxime (n=108) or placebo (n=57). Five patients in the olesoxime group were not included in the 
primary outcome analysis because of an absence of post-baseline assessments. The change from baseline to month 24 
on the primary outcome measure was 0·18 for olesoxime and –1·82 for placebo (treatment difference 2·00 points, 
96% CI –0·25 to 4·25, p=0·0676). Olesoxime seemed to be safe and generally well tolerated, with an adverse event 
profile similar to placebo. The most frequent adverse events in the olesoxime group were pyrexia (n=34), cough 
(n=32), nasopharyngitis (n=25), and vomiting (n=25). There were two patient deaths (one in each group), but these 
were not deemed to be related to the study treatment. 
 
Interpretation Olesoxime was safe at the doses studied, for the duration of the trial. Although the primary endpoint 
was not met, secondary endpoints and sensitivity analyses suggest that olesoxime might maintain motor function in 
patients with type 2 or type 3 SMA over a period of 24 months. Based on these results, olesoxime might provide 
meaningful clinical benefits for patients with SMA and, given its mode of action, might be used in combination with 
other drugs targeting other mechanisms of disease, although additional evidence is needed. 
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Introduction 
Spinal muscular atrophy (SMA) is a rare and severely 
debilitating neuromuscular disease that manifests 
predominantly in infancy and childhood.1,2 In type 2 and 
type 3 SMA, the deterioration of motor function results in 
substantial disability and in patients and a high burden 
for their caregivers.3 SMA is caused by loss-of-function 
mutations in the Survival of Motor Neuron 1 (SMN1) 
gene. The absence of the SMN1 gene results ininsufficient 
levels of SMN protein in cells, which particularly affect 
motor neurons and neuromuscular junctions, leading to 
muscle weakness, hypotonia, and atrophy.1,4 
Although reduced SMN protein levels impair many 
fundamental neuronal processes and are the triggering 
event in all SMA types, the downstream pathological 
consequences of atrophy and denervation are also related 
to mitochondrial dysfunction, which also affects other 
cell types.5–8 Given their role on energy production, 
mitochondria are vital for cells with a high energy 
demand, including motor neurons and muscle fibres 
that are central to the pathophysiology of SMA.5,7,9,10 
Current therapies in clinical development have aimed to 
increase SMN production systemically, either by replacing 
SMN1 (eg, gene therapy with AVXS-101) or by SMN2 
splicing modulators (eg, RO6885247, RO7034067, and 
LMI070). Nusinersen, a SMN2 splicing modulator for 
intrathecal administration, has been approved by the US 
Food and Drug Administration for treatment of SMA.11 
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Research in context 
Evidence before this study 
Approved treatment for spinal muscular atrophy (SMA) is 
limited to nusinersen, an intrathecal-administered, antisense 
oligonucleotide intended to restore deficient SMN protein 
concentrations in motor neurons. However, unmet medical 
need remains in patients with SMA for additional, potentially 
complementary therapies that delay disease progression or 
augment the benefit of other therapies; substantial efforts have 
been invested to identify the key mechanisms of disease and 
test potential compounds. There is growing evidence that 
mitochondrial dysfunction is a key mechanism and a valid 
therapeutic target in neurological diseases, including SMA. 
In-vitro studies showed that olesoxime localises at the 
mitochondrial membrane, where it increases functional 
integrity of mitochondria in cortical neurons, and protects 
against apoptosis by preventing release of pro-apoptotic 
cytochrome C. At the time of study design for the present trial, 
only one large multicentre efficacy study had been done, 
assessing riluzole in patients with type 1 SMA (NCT 00774423), 
for which results had not been published. 
Added value of this study 
This study is the largest and longest international study done 
so far in patients with SMA, and evaluates the safety and 
efficacy of olesoxime in a population of patients with type 2 or 
 
 
However, therapies that augment SMN levels might not 
benefit all patients, based on evidence from mouse 
models.12 Consequently, an important role might exist for 
systemic non-SMN therapies that target alternative 
mechanisms, possibly in a complementary or synergistic 
manner, which might maintain motor units, muscle cells, 
and other affected cell types, particularly in the 
slowdegenerative phase of the disease. 
Olesoxime prevents excessive permeability of the 
mitochondrial membrane under stress conditions,13–15 
preventing apoptosis by reducing the release of pro- 
apoptotic factors and maintaining energy production.13–15 
Olesoxime showed neuroprotective and neuro- 
regenerative effects in several animal models of motor 
nerve degeneration, reducing pro-apoptotic factor 
release from neuronal mitochondria.13,16 In a transgenic 
mouse model of severe SMA (SMNF7/F7; NSE-Cre mice), 
daily olesoxime administration extended survival 
compared with vehicle-treated mice.13 Taken together, 
these data suggest that olesoxime might maintain motor 
neuron function and might be a therapeutic drug in the 
treatment of SMA.13,16 
Following a phase 1 study in SMA that assessed 
preliminary safety, tolerability, and pharmacokinetics,17 
accompanied by safety data in a phase 2/3 trial in 
amyotrophic lateral sclerosis,18 this phase 2 study aimed 
to assess the safety, tolerability, and efficacy of olesoxime 
in patients with type 2 or non-ambulatory type 3 SMA. 
 
 
 
type 3 SMA. Although the study did not meet the primary 
endpoint, secondary endpoints and sensitivity analyses of the 
primary endpoint suggest some indications of efficacy in terms 
of maintenance of motor function over 2 years. Recent 
evidence suggests that maintenance of motor function is a key 
aspiration for patients with SMA as it preserves activities of 
daily living. The study also allowed, for the first time, the 
prospective assessment of motor function using both the 
Motor Function Measure and Hammersmith Functional Motor 
Scale, providing novel data for these measures in a large 
controlled study setting over a 24-month period. 
Implications of all available evidence 
The results of this study support the continued development of 
olesoxime as a therapy for SMA, a progressive, debilitating 
disease with reduced life expectancy, for which only one 
approved therapy exists. The clinical development of olesoxime 
will continue with an open-label extension study for patients 
previously treated in the phase 2 study (NCT02628743), and a 
phase 3 trial is being planned. Given the paucity of approved 
treatments for patients with SMA, the results of this study 
provide both invaluable information for future trial design and 
encouraging evidence on the part that olesoxime might play as 
a novel drug for SMA. 
 
 
 
Methods 
Study design and participants 
We did a randomised, double-blind, placebo-controlled 
phase 2 study in 22 neuromuscular care centres in 
Belgium, France, Germany, Italy, Netherlands, Poland, 
and the UK (appendix). All sites were centres with 
expertise in treating patients with SMA in line with the 
published standards of care for SMA. 
Patients aged 3–25 years with type 2 or non-ambulatory 
type 3 SMA were recruited mainly via information 
disseminated through the TREAT-NMD website, patient 
registries, and in the clinics at each site, and were eligible 
for inclusion if they had weakness and hypotonia 
consistent with a clinical diagnosis of SMA type 2 or 3; 
genetic diagnosis of SMA with homozygous deletion of 
SMN1 exon 7, or a heterozygous deletion accompanied by 
a point mutation on the other allele; Motor Function 
Measure (MFM) relative score (percentage of the 
maximum sum of both dimensions) of 15% or higher 
(functional domain 1 [D1] plus functional domain 2 [D2] 
score); Hammersmith Functional Motor Scale (HFMS) 
score at baseline between 3 and 38 (non-ambulatory); 
onset of symptoms at 3 years of age or younger; and ability 
to take the study treatment (tested at screening after 
informed consent). Key exclusion criteria included 
substantial central nervous system impairment, neuro- 
degenerative or neuromuscular disease other than SMA, 
and use of drugs intended for the treatment of SMA. A full 
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list of criteria is available in the appendix. All patients or 
their parent or guardian provided written informed 
consent before screening. The study was approved by local 
institutional review boards and ethics committees. 
 
Randomisation and masking 
Patients were randomly assigned in a 2:1 ratio to receive 
olesoxime or placebo, with stratification by SMA type 
and centre. A 2:1 randomisation as a means to limit 
placebo exposure was deemed more ethically acceptable in 
a progressive, debilitating disease with no available 
treatment options. Randomisation lists were generated 
centrally by an independent statistician (Business & 
Decision Life Sciences, Montrouge, France) using validated 
randomisation software (SAS version 9.2, SAS Institute 
Inc, Cary, NC, USA). To maintain masking, active and 
placebo treatments were supplied in brown glass bottles, 
and randomisation details were provided using secure 
procedures to the clinical research organisation that did 
the packaging of the treatment units and to the laboratory 
that did the olesoxime pharmacokinetics bioanalysis assay. 
All investigators, site personnel, patients, and the sponsor 
study personnel were masked to treatment assignment 
until completion of the study. 
 
Procedures 
Patients received oral olesoxime 100 mg/mL liquid 
suspension formulation (manufactured by Minakem, 
Beuvry-la-Forêt, France, and packaged by CRID 
PHARMA, Saint-Gély-du-Fesc, France) at a weight-based 
fixed dose of 10 mg/kg once a day or matching placebo 
with their main daily meal for 24 months. After screening 
and baseline visits, follow-up visits were scheduled for 
week 4 and week 13 after randomisation, after which 
participants were assessed every 13 weeks for a total of 
nine visits over the 24-month treatment period. The full 
schedule of assessments is provided in the appendix. An 
interim efficacy analysis was done by an independent 
statistician when all patients  had  been  treated  for 
12 months, to assess the need to continue the study to 
reach the planned objective. In the event of positive and 
significant results in favour of olesoxime, the study was 
to be considered successful and all patients were to be 
switched to olesoxime to allow assessment of the 
sustainability of the treatment effect and safety. If the 
results were significantly in favour of placebo, the study 
was to be discontinued for failure (futility). The interim 
efficacy analysis was reviewed by an independent Data 
Monitoring Committee. The final efficacy and safety 
analysis was done using data at 24 months. 
 
Outcomes 
The primary outcome measure was the change from 
baseline between treatment groups to month 24 as 
assessed by D1 + D2 of the 32-item MFM (MFM32).19 A 
shorter 20-item version (MFM20) specifically adapted for 
young  children20  was  used  to  assess  children aged 
younger than 6 years. The MFM assesses standing, 
ambulation and transfers, and axial, proximal, and distal 
function (appendix). 
Secondary outcomes were responder analyses of the 
change from baseline to month 24 in total MFM score, 
individual MFM domains (D1, D2, and D3), and HFMS 
from baseline to month 21; the proportion of patients 
showing maintenance or improvement in scores on MFM 
D1 + D2, MFM total score (D1 + D2 + D3), and HFMS 
change from baseline to month 21. Secondary endpoints 
assessing non-motor function were maximum compound 
muscle action potential (CMAP) and motor unit number 
estimation (MUNE); clinical global impression of change 
(CGI-C) assessed by the patient or caregiver and a 
physician; forced vital capacity (FVC); and Pediatric 
Quality of Life Inventory (PEDsQL) Neuromuscular 
Module (appendix).21 
Safety assessments were adverse events, standard 
laboratory assessments, electrocardiograms, and vital 
signs. The independent Data Monitoring Committee was 
responsible for monitoring the safety of patients by 
reviewing data every 13 weeks. The committee also 
reviewed olesoxime plasma trough concentrations at 
weeks 4 and 13, and reviewed the efficacy data at week 52 
to make a recommendation on study continuation. 
Sensitivity analyses of the primary endpoint, which 
were prespecified in the statistical analysis plan following 
the interim analysis, were subgroup analyses of MFM D1 
+ D2 score to assess the overall treatment effect at month 
24, and effect of age, country, and SMA type. In post-hoc 
sensitivity analysis, we assessed the effect of olesoxime 
exposure on the primary outcome measure (appendix). 
 
Statistical analysis 
Based on natural history studies,22 we estimated that a 
mean decrease of 1·9 points in the MFM D1 + D2 score 
would be observed over 24 months in the placebo group, 
and no worsening of motor function in the olesoxime 
group, with an assumed SD of 3·32. To test whether 
olesoxime would prevent worsening of motor function 
over 24 months, we  calculated  that  150  patients  
(100 receiving olesoxime and 50 receiving placebo) would 
be needed to reach a power of at least 85% (α=0·04 to 
take into account the interim efficacy analysis done after 
12 months [α=0·01]), assuming 5% of patients would be 
lost to follow-up. 
All efficacy analyses were based on the full analysis set, 
which includes all randomly assigned patients who 
received at least one dose of olesoxime or placebo and 
who had at least one post-randomisation assessment of 
MFM available. All safety analyses are based on the safety 
evaluable population (all randomly assigned patients 
who received at least one dose of the study drug). 
In 17 patients (olesoxime n=12, placebo n=5) who were 
younger than 6 years at enrolment, MFM32 was used at 
all visits instead of the protocol-defined MFM20. To 
account for this, we did two separate analyses of MFM 
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Data are n (%) or mean (SD), unless otherwise stated. SMA=spinal muscular atrophy. 
 
Table 1: Baseline demographic and clinical characteristics 
57 allocated to placebo 
5 excluded from the full 
analysis set (absence of 
post-baseline  assessme 
33 excluded 
30 did not meet inclusion criteria 
2 declined to participate 
1 had coagulopathy (Von 
Willebrand syndrome) 
10 patients withdrew before the 
end of the study 
4 had adverse events 
3 withdrew consent 
2 withdrew for other reasons 
1 died 
7 patients withdrew before the 
end of the study 
2 had adverse events 
1 withdrew consent 
1 due to non-compliance 
1 died 
198 patients assessed for eligibility 
165 enrolled and randomly assigned 
108 allocated to olesoxime 
108 included in safety population 
103 included in the full-analysis set 57 included in the full-analysis set 
 
 
 
 
 
 
 
 
 
 
 
57 included in safety population 
 
 
 
ts) 
 
 
 
 
 
 
 
 
 
Figure 1: Trial profile  
 
 
Olesoxime 
 
 
 
Placebo 
 
 
 
Total 
 (n=103) (n=57) (n=160) 
Male 55 (53%) 25 (44%) 80 (50%) 
Female 48 (47%) 32 (56%) 80 (50%) 
Age (years)    
Mean 9·1 (5·5) 11·2 (6·0) 9·9 (5·7) 
Median (range) 7 (3–25) 11 (3–27) 8 (3–27) 
Age   
<6 years 35 (34%) 13 (23%) 48 (30%) 
≥6 years 68 (66%) 44 (78%) 112 (70%) 
SMA type 
Type 2 
 
74 (72%) 
 
39 (68%) 
 
113 (71%) 
Type 3 29 (28%) 18 (32%) 47 (29%) 
 
 
 
 
score. In the primary analysis, a score for the MFM20 was 
calculated from the MFM32 score for these 17 patients by 
using only the 20 items that are featured in MFM20. 
A secondary sensitivity analysis included data from 
whichever form of the MFM that was used. 
The primary outcome, change from baseline to month 
24 in MFM D1 + D2 between treatment groups, was 
analysed using a mixed-effects repeated measures 
(MMRM) model. Covariates in the primary model were 
MFM score (D1 + D2) at baseline, SMA type, country, 
treatment group, visit, and treatment group by visit 
interaction. Further detail on the model is provided in the 
appendix. Least-square means, SEs, and the 96% CIs of 
treatment difference between olesoxime and placebo were 
reported. Statistical tests for the primary analysis were 
done with a two-sided test with a significance level (α) 
of 4%. 
CGI-C ratings were analysed with a van Elteren test, a 
non-parametric test that compares the ranks of 
responses, stratified by country. Other secondary 
endpoints were tested with two-sided tests with a 
significance level (α) of 5% (appendix). 
For the post-hoc analysis of the primary outcome 
measure according to olesoxime exposure, the time 
course of the mean change from baseline (standard error 
of mean [SEM]) of the MFM D1 + D2 score was graphically 
compared between patients with low and high olesoxime 
exposure and the placebo group (appendix). A post-hoc 
responder analysis of CGI-C mirroring the responder 
analyses for the MFM and HFMS was also done. Patients 
rated as no change or better (ie, stability or improvement) 
were considered to be responders, and patients rated as 
minimally worse or worse (ie, deterioration) were 
considered to be “non-responders”. The proportion of 
responders and non-responders was then compared 
across treatment groups with a log binomial model, 
controlling for SMA type. 
Adverse events were reported at each patient visit and 
traced in source documents, which were then monitored, 
with all adverse events reported in an electronic case 
report form by the investigation sites. Additionally, a post- 
hoc analysis was done on a series of adverse events 
clusters defined as SMA-related complications (appendix). 
All analyses were done with SAS software (version 9.2). 
This study is registered with ClinicalTrials.gov,  number 
NCT01302600. 
 
Role of the funding source 
AFM-Téléthon designed the study. J-LA was an employee 
of Trophos SA and was responsible for protocol 
development and study supervision until enrolment was 
completed. ED was an employee of Trophos SA and 
participated in the study management, data collection, 
data management, and data analysis. Five authors (TB, 
PF, CR, PSD and EV) are employed by F Hoffman La 
Roche and did primary, sensitivity, and exploratory 
analyses of this study. The funders of the study had no 
other role in data interpretation or in the decision to 
submit the manuscript for publication. Roche also 
supported reporting of study results by funding medical 
writing support. All authors had full access to all data in 
the study and had final responsibility for the decision to 
submit for publication. 
Results 
Between Nov 18, 2010, and Sept 6, 2011, 165 patients were 
enrolled and randomly assigned to treatment. Of these, 
108 patients received olesoxime and 57 patients received 
placebo (figure 1). The final visit occurred on Oct 9, 2013. 
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17 patients withdrew prematurely, ten (12%) from the 
olesoxime group and seven (9%) from the placebo group. 
Of 108 patients allocated to olesoxime, five patients were 
excluded from the full analysis set because of the absence 
of post-baseline assessments. Protocol violations occurred 
in 30 patients (19 [18%] receiving olesoxime, 11 [19%] 
receiving placebo), including the 17 patients younger than 
6 years at enrolment who did the MFM32 assessment at 
all visits instead of the protocol-defined MFM20. Other 
major protocol violations (olesoxime n=7 and placebo 
n=6) included deviation from the inclusion screening 
criteria (use of forbidden drugs and spinal rod or fixation 
for scoliosis within 6 months of enrolment), abnormal 
liver enzymes (alanine aminotransferase or aspartate 
aminotransferase >3 times the upper limits of normal), 
treatment compliance of 50% for at least two visits, and 
delayed visit dates. The full analysis set used for all 
efficacy analyses comprised 160 patients (table 1). 
Patient demographic and baseline characteristics were 
mainly well balanced between the treatment groups, 
including proportions of patients with type 2 or type 3 
SMA. However, both mean and median ages were lower 
in the olesoxime group than in the placebo group, with a 
difference of 2·1 years in mean ages and a difference of 
4 years in median ages across treatment groups (table 1). 
Additionally, there were slight differences in the 
proportion of males and females between groups. The 
interim efficacy analysis done at month 12 did not find a 
significant difference between treatment groups. 
Therefore, the study continued with the full 2-year 
treatment period. 
For the primary outcome, patients receiving olesoxime 
treatment had a mean change in MFM D1 + D2 score 
from baseline to month 24 of 0·18 points, whereas the 
placebo group had a mean change of –1·82 points. The 
difference  was  not  significant  (2·00  points,  96% CI 
–0·25 to 4·25, p=0·0676; table 2). 
The secondary outcome examining overall treatment 
difference across all visits was 2·23 points (96% CI 
0·50–3·96), and was statistically significant in favour of 
olesoxime (p=0·0084; figure 2). All other secondary 
MFM and HFMS endpoints were not significantly 
different between groups (table 3, appendix). In the 
responder analysis, the percentage of responders was 
significantly higher in the olesoxime group than in the 
placebo group for the MFM total score (56% for 
olesoxime, and 39% for placebo; p=0·0419; table 4). The 
proportion of patients who improved or remained stable 
over 21 months (response rate) on the HFMS was 
significantly higher in the olesoxime group than in the 
placebo group (50% for olesoxime and 28% for placebo, 
p=0·0091; table 4). Secondary outcomes assessing non- 
motor function with CMAP, MUNE, CGI-C, FVC, and 
PEDsQL Neuromuscular Module were not significantly 
different between groups (appendix). 
Olesoxime seemed generally safe and well tolerated, and 
approximately equivalent proportions of patients in each 
group experienced at least one adverse event during the 
study (table 5); several adverse events were frequently 
reported (>5%), with fairly equal frequency in both 
treatment groups (appendix). Two patients died during 
the study, with one death in each treatment group, but 
these deaths were not deemed to be related to treatment 
by the treating physicians (attributed to cardiac arrest in 
the patient in the olesoxime group; and attributed to 
increased bronchial secretion in the patient in the placebo 
group; appendix). A greater proportion of patients 
experienced serious adverse events in the placebo group 
than in the olesoxime group (table 5). The proportion of 
patients withdrawing from treatment because of adverse 
events was low (4% for both olesoxime and placebo 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Adjusted mean change in MFM D1 + D2 score from baseline to months 6, 12, 18, and 24 
For children younger than 6 years who erroneously did the MFM32 assessment, MFM20 score was calculated from 
MFM32 score. Error bars represent standard error of the mean. MFM=Motor Function Measure. *Primary outcome. 
Olesoxime Placebo 
(n=103) (n=57) 
Estimate 
(SE) 
96% CI p value 
Primary analysis 
Mean baseline 
Least-squares mean change 
from baseline to week 104 
96% CI 
Difference from placebo 
(primary outcome) 
Sensitivity analysis 
39·58 (11·701) 
0·18 (0·717) 
38·99 (11·905) ·· 
–1·82 (0·901) ·· 
·· 
·· 
·· 
·· 
–1·30 to 1·66 
·· 
–3·68 to 0·04 
·· 
·· 
2·00 (1·088) 
·· 
–0·25 to 4·25 
·· 
0·0676 
Data are least-squares mean (SE) or mean (SD), unless otherwise stated. Primary analysis: comparison between treatment 
groups on change from baseline at month 24 in MFM D1 + D2 score (MMRM; full analysis set). For children aged <6 years 
who erroneously did the MFM32 assessment, MFM20 score was calculated from MFM32 score. Sensitivity analysis: data as 
collected from whichever form of the MFM was used (see appendix for methods). D1 + D2 MFM=domains 1 and 2 of the 
Motor Function Measure. MMRM=mixed model-repeated measures. 
Table 2: Primary and prespecified sensitivity analyses 
Mean baseline 
Least-squares mean change 
from baseline to week 104 
95% CI 
Difference from placebo 
Overall treatment effect 
39·01 (11·472) 
0·24 (0·696) 
38·69 (11·689) ·· 
–1·96 (0·872) ·· 
·· 
·· 
·· 
·· 
–1·14 to 1·61 
·· 
·· 
–3·68 to –0·24 
·· 
·· 
·· 
2·20 (1·050) 
2·36 (0·817) 
·· 
0·12 to 4·27 
0·74 to 3·97 
·· 
0·0379 
0·0044 
1 
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groups at timepoint 
p value 
2·41 
12 
Time (months) 
1·77 
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groups). A post-hoc analysis investigating disease-related 
adverse events (appendix) showed a higher incidence in 
the placebo group than in the olesoxime group, with a 
lower frequency of the following disorders with olesoxime 
treatment: lower respiratory tract infections, gastro- 
intestinal disorders (reflux disorders and constipation), 
and other joint-related disorders (table 5). 
 
In the sensitivity analysis of the primary outcome, 
taking into account erroneous use of the MFM32 version 
in some patients younger than 6 years, the difference in 
change from baseline between the two treatment groups 
was statistically significant in favour of olesoxime (2·20, 
95% CI 0·12–4·27, p=0·0379). The change from baseline 
in MFM D1 + D2 score is shown separately for three 
different age groups: younger than 6 years, 6–15 years, 
and older than 15 years (figure 3). In the 6–15 years 
group, patients in the olesoxime group showed 
improvements in scores compared with baseline at all 
timepoints and patients in the placebo group showed a 
consistent decline (>3-point difference between 
treatments at all visits; overall mean p=0·0107). In the 
other age groups, no significant differences were 
observed between the treatment groups. 
Prespecified sensitivity analyses of the MFM D1 + D2 
score revealed effects of olesoxime across country (data 
not shown), SMA type, sex, and disease severity at 
baseline (appendix). Analysis of the primary endpoint 
that included age as a continuous covariate revealed no 
significant effect of age on MFM D1 + D2 scores 
(p=0·2481; data not shown). The effects of olesoxime on 
the HFMS were observed across country (data not 
shown), age, SMA type, and sex (appendix). 
In a post-hoc sensitivity analysis, the difference 
between olesoxime-treated and placebo-treated patients 
at month 24 was 3·61 points (p=0·036; figure 3). In the 
post-hoc responder analysis of CGI-C, a statistically 
significant effect favouring olesoxime over placebo was 
observed for CGI-C with physician-reported data (relative 
risk [RR] 1·23, 95% CI 1·01–1·49, p=0·036). 
In post-hoc MMRM analyses, changes from baseline in 
MFM D1 + D2 score were repeated with systematic, one- 
by-one exclusion of patients with the lowest pharma- 
cokinetic exposure values (Cavg; appendix). The smallest 
MMRM p value (p=0·0088) was obtained for a Cavg of 
7500 ng/mL. This value was reached after exclusion of 
37 patients with the lowest exposure. Cavg values for the overall olesoxime treatment group and two groups 
the 
with exposure levels below or above this value (7500 ng/mL) 
are shown in the appendix. Patients with olesoxime 
exposure 7500 ng/mL or more showed improvements in 
MFM D1 + D2 score at all visits, with a 2·0-point 
improvement from baseline at month 24 (appendix). The 
group with olesoxime exposure of less than 7500 ng/mL 
showed a decrease in MFM D1 + D2 score. 
Discussion 
This phase 2 clinical trial tested the hypothesis that oral 
administration of olesoxime (10 mg/kg per day) would at 
least prevent decline of, and potentially improve, motor 
function in patients with type 2 or non-ambulatory type 3 
SMA over a treatment period of 2 years, while patients in 
the placebo group would show a decline in motor 
function in line with the natural history of the disease. 
The trial did not meet the primary outcome of improved 
MFM D1 + D2 (to month 24) 
MFM total score (to month 24) 
HFMS (to month 21) 
Olesoxime  (n=103) 
56 (54%) 
58 (56%) 
51 (50%) 
Placebo (n=57)   Relative risk (95% CI)   p value 
22 (39%) 
22 (39%) 
16 (28%) 
1·43 (0·98–2·08) 
1·46 (1·01–2·10) 
1·82 (1·16–2·86) 
0·0609 
0·0419 
0·0091 
For children younger than 6 years who erroneously did the MFM32 assessment, MFM20 score was calculated from 
MFM32 score. MFM=Motor Function Measure. D1=MFM domain 1 (standing position and transfers). D2=MFM 
domain 2 (axial and proximal motor function). HFMS=Hammersmith Functional Motor Scale. 
Table 4: Secondary analysis of responders according to motor function scores 
Olesoxime 
(n=103) 
MFM total score (to month 24) 
Placebo 
(n=57) 
Estimate 
(SE) 
95% CI p value 
Mean baseline 
Least-squares mean change 
from baseline to week 104 
95% CI 
Difference from placebo 
MFM D1 (to month 24) 
Mean baseline 
Least-squares mean change 
from baseline to week 104 
95% CI 
Difference from placebo 
MFM D2 (to month 24) 
Mean baseline 
Least-squares mean change 
from baseline to week 104 
95% CI 
Difference from placebo 
MFM D3 (to month 24) 
Mean baseline 
Least-squares mean change 
from baseline to week 104 
95% CI 
Difference from placebo 
HFMS (to month 21) 
Mean baseline 
Least-squares mean change 
from baseline to week 91 
95% CI 
Difference from placebo 
49·32 (10·993) 
0·59 (0·751) 
49·11 (11·432) ·· 
–1·45 (0·943) ·· 
·· 
·· 
·· 
·· 
–0·90 to 2·07 
.. 
–3·31 to 0·41 
.. 
·· 
2·04 (1·138) 
·· 
–0·21 to 4·28 
·· 
0·0755 
6·76 (7·933) 
0·07 (0·554) 
7·28 (7·543) 
–0·90 (0·706) 
·· 
·· 
·· 
·· 
·· 
·· 
–1·02 to 1·16 
·· 
–2·29 to 0·49 
·· 
·· 
0·97 (0·854) 
·· 
–0·72 to 2·66 
·· 
0·2582 
74·10 (18·610) 
0·38 (1·217) 
72·64 (18·882) 
–2·78 (1·524) 
·· 
·· 
·· 
·· 
·· 
·· 
–2·02 to 2·78 
·· 
–5·79 to 0·23 
·· 
·· 
3·16 (1·838) 
·· 
–0·47 to 6·79 
·· 
0·0873 
85·41 (13·147) 
2·27 (1·264) 
86·05 (15·412) 
0·15 (1·606) 
·· 
·· 
·· 
·· 
·· 
·· 
–0·22 to 4·76 
·· 
–3·02 to 3·32 
·· 
·· 
2·12 (1·945) 
·· 
–1·72 to 5·96 
·· 
0·2773 
16·47 (10·576) 
–0·78 (0·416) 
14·86 (10·514) 
–1·72 (0·515) 
·· 
·· 
·· 
·· 
·· 
·· 
–1·60 to 0·04 
·· 
–2·74 to –0·70 
·· 
·· 
0·94 (0·622) 
·· 
–0·28 to 2·17 
·· 
0·1309 
Data are least-squares mean (SE) or mean (SD), unless otherwise stated. Primary analysis: for children aged younger 
than 6 years who erroneously did the MFM32 assessment, MFM20 score was calculated from MFM32 score. Sensitivity 
analysis: data as collected from whichever form of the MFM was used (appendix). MFM=Motor Function Measure. 
D1=MFM domain 1 (standing position and transfers). D2=MFM domain 2 (axial and proximal motor function). 
D3=MFM domain 3 (distal motor function). HFMS=Hammersmith Functional Motor Scale. 
Table 3: Secondary motor function outcomes 
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  Olesoxime (n=108)   Placebo (n=57) 
Patients with ≥1 adverse event 103 (95%) 57 (100%) 
Number of adverse events 1104 612 
Total (n=165) 
160 (97%) 
1716 
outcome 
 
Patients with ≥1 adverse event leading to 
withdrawal from study 
Patients with ≥1 severe adverse event 
Disease-related adverse events (post-hoc) 
9 (8%) 2 (4%) 11 (7%) 
18 (17%) 14 (25%) 32 (19%) 
Data are n (%). See appendix for breakdown of adverse events by type. 
 
Table 5: Adverse events 
 
motor function, compared with placebo, as measured by 
change from baseline to month 24 in MFM D1 + D2 
score. However, several positive secondary outcomes 
suggest   that   olesoxime   might   be   helpful   in  the 
 
 
 
 
groups was significantly in favour of olesoxime at 
months 6 and 18, as well as in a sensitivity analysis taking 
into account erroneous use of MFM32 assessment in 
some patients younger than 6 years. Second, the change 
from baseline on MFM D1 + D2 scores was significantly 
better with olesoxime treatment than with placebo in 
patients aged 6–15 years during the entire treatment 
period. Patients with SMA in this age group generally 
experience profound declines in motor function 
associated with puberty.23,24 Given that the expected effect 
of olesoxime was primarily maintenance of function, and 
that demonstration of a treatment effect would therefore 
depend on functional decline in the placebo group, we 
might expect that the greatest effect would be observed in 
this age group. In fact, the results might suggest a change 
in the trajectory of motor function with olesoxime in 
6–15 year olds exists, from decline to improvement. Such 
differences between treatment groups were not observed 
in the youngest (<6 years) and oldest (>15 years) age 
groups. This might be because children younger than 
6 years might experience improvements in motor 
function as they develop and achieve motor function 
milestones,25 whereas patients older than 15 years might 
experience periods of fairly stable function over 2–3 years 
of observation.23,24 Third, in a post-hoc sensitivity analysis, 
we observed that response on the primary outcome 
measure was associated with olesoxime exposure, with 
patients that experienced higher olesoxime exposure also 
showing improved responses. Finally, we also observed 
positive effects of olesoxime treatment in the responder 
analyses of the MFM total score and HFMS, in which a 
significantly greater proportion of patients receiving 
olesoxime than patients receiving placebo showed stable 
or improved motor function over the study period. These 
results were supported by the post-hoc responder analysis 
of CGI-C, a measure of global change relative to baseline, 
in which a significant benefit of olesoxime treatment 
compared with placebo was observed in the proportion of 
patients with stable or improved overall status as assessed 
by physicians. This benefit might represent additional 
evidence supportive of a clinically relevant effect of 
olesoxime, although further study is needed. 
Given that many of the analyses showed signs of efficacy 
for olesoxime, it is perhaps surprising that olesoxime did 
not achieve significance on the primary outcome measure. 
A potential explanation relates with the higher than 
anticipated variability observed on the primary outcome 
measure in the study population, which caused the study 
 
 
 
 
Lower respiratory tract infections 13 (12%) 10 (18%) 23 (14%) 
Respiratory failure 2 (2%) 2 (4%) 4 (2%) 
Reflux disorders 4 (4%) 4 (7%) 8 (5%) 
Constipation 5 (5%) 4 (7%) 9 (5%) 
Scoliosis 14 (13%) 6 (11%) 20 (12%) 
Other joint-related disorders 13 (12%) 17 (30%) 30 (18%) 
Surgical procedure 9 (8%) 5 (9%) 14 (8%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Adjusted mean change in MFM D1 + D2 scores from baseline to month 24, by age group 
For children younger than 6 years who erroneously did the MFM32 assessment, MFM20 score was calculated from 
MFM32 score (see appendix for full explanation). Error bars represent standard error of the mean. MFM=Motor 
Function Measure. 
 
to be underpowered. Our sample size calculation was 
based on a change of –1·9 points in MFM score in the 
placebo group over 24 months, with no worsening in the 
olesoxime group, and an assumed SD of 3·3. In fact, we 
observed a standard deviation for MFM D1 + D2 of 
6·8 points in the placebo group, with a treatment 
difference of 2·0, in a population of 160 patients; this was 
greater than the variability reported in two previous 
longitudinal studies of motor function measures in 
patients with SMA.3,26 
The greater variability observed in our population 
might  have  arisen  from  several  causes,  including 
2 
 
 
0 
 
 
–2 
 
Placebo (n=57) 
–4           Olesoxime (n=103) 
3–<6 
 
13 
35 
0·7459 
44·07 (10·65) 
45·89 (10·67) 
6–15 
Age (years) 
25 
54 
0·0362 
36·48 (12·14) 
37·53 (11·07) 
>15 
Placebo (n) 
Olesoxime (n) 
p value for treatment difference 
Placebo, mean MFM D1+D2 (SD) 
Olesoxime, mean MFM D1+D2 (SD) 
19 
14 
0·9602 
38·81 (11·95) 
31·71 (9·29) 
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) 
maintenance of motor function. Deaths 1 (1%) 1 (2%) 2 (1%) 
First, the overall treatment effect in terms of change 
from baseline on MFM D1 + D2 across all visits was 
Patients who withdrew from the study due to an 
adverse event 
4 (4%) 2 (4%) 6 (4%) 
significantly better with olesoxime than  with placebo. Patients with ≥1 adverse event with fatal 1 (1%) 1 (2%) 2 (1%) 
Additionally, the difference between the two treatment Patients with ≥1 serious adverse event 34 (31%) 29 (51%) 62 (38%) 
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imputation of scores in cases of death or missing data, 
erroneous use of the MFM32 in some patients younger 
than 6 years, and a relatively wide age range with 
significant variation in stages of development and 
differences in potential motor function decline.24 Our 
study also lacked an inclusion criterion relating to 
standard of care, which might have resulted in a 
heterogeneous population in terms of previous 
intervention. Assessment and comparison of non- 
pharmacological management was not possible. 
However, all patients were treated in Europe and the 
cohort was stratified across countries, with no significant 
effect of country observed in the subgroup analyses. 
However, it is possible that the increased variability 
might arise from the differing contexts of the previous 
studies versus the present one. The previous studies4,26 
did not include any treatment, and the absence of any 
expectation of improvement by the patients might in 
itself produce more homogeneous results. Furthermore, 
because the overall aim of the previous studies was to 
validate motor function scales, the methods would have 
been more closely focused on demonstrating 
repeatability and reproducibility, again leading to more 
homogeneous data. 
On the secondary endpoints CMAP, MUNE, PEDsQL, 
and FVC, no clear benefit of olesoxime treatment was 
observed (appendix). The correlation between CMAP and 
MUNE measurements and disease progression in SMA 
is uncertain and differences have been observed between 
SMA types,27 so these measures might not be expected to 
show any evidence of consistent changes across the 
study. Furthermore, gaps exist in establishing the 
validation and sensitivity of the PEDsQL in patients with 
SMA because factor analysis to explore construct validity 
and dimensionality has not been done yet.22 For FVC, 
post-baseline height was not measured, which prevented 
accurate calculation of predicted FVC after this time, and 
intersite variation might have played a part with different 
equipment used to perform this measure. On CGI-C, the 
initial analysis might not have been powerful enough to 
detect differences when the majority of responses 
reported no change. The results at month 24 relied on 
the accuracy of a 2-year recall, which might be too long 
for optimum assessment.28 Additionally, no instructions 
were provided to assessors on how to rate clinical change 
when completing the scale (eg, what should be 
considered a minimum improvement or worsening), 
resulting in potential inconsistency among respondents. 
These endpoints will require refinement before use in 
future trials of SMA, and intercentre performance would 
be improved by using standardised methods across study 
sites. 
Olesoxime seemed safe and well tolerated, and a post- 
hoc analysis suggested that fewer patients receiving 
olesoxime experienced disease-related complications, 
including pulmonary, gastrointestinal, and joint-related 
disorders. 
An ongoing difficulty with research in SMA is 
translating available trial endpoints for measurement of 
motor function into clinically meaningful benefits for 
patients. Further investigations are ongoing to investigate 
the treatment effects of olesoxime on specific items of the 
motor function scales that can be better related to a 
patient’s activities of daily living and developmental needs. 
However, there are strong indications from physician 
experience of treating patients with SMA and from direct 
discussions with patients and caregivers that maintenance 
of function is regarded by patients and their families as a 
meaningful outcome.3,29 
A limitation of the study was the interindividual 
variability in olesoxime exposure. Daily doses 
approaching 1000 mg administered over 2 years were 
well tolerated, suggesting that the therapeutic window 
might be sufficiently wide for the administration of 
higher doses of olesoxime, to maximise benefit. 
Additional trials exploring higher doses might offer the 
opportunity to conclusively assess the efficacy of 
olesoxime. A further limitation is the absence of bio- 
markers to measure disease progression and the expected 
biological function of olesoxime. Despite the 
acknowledged limitations, this study represents a 
landmark, being the longest and largest international, 
controlled study so far to collect prospective assessments 
with both the MFM and HFMS motor scales. These 
novel data are useful to improve the design of future 
studies in similar populations of patients with SMA. 
Based on these results, olesoxime might provide 
meaningful clinical benefits for patients with SMA and, 
given its mode of action, might be used in combination 
with other drugs targeting other mechanisms of disease. 
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